115 related articles for article (PubMed ID: 37948339)
41. Effects of Tegafur, Gimeracil and Oteracil Potassium Capsules combined with Calf Spleen Extractive Injection on serum VEGF and MMP-9 in patients with advanced gastric cancer.
Zhang Y; Zhong Q; Luo X; Zhang W
Am J Transl Res; 2022; 14(11):7969-7976. PubMed ID: 36505301
[TBL] [Abstract][Full Text] [Related]
42. [Effect of interleukin 17 on invasion of human colon cancer cells].
Chen Z; Cao J; Yang P; Liu Z; Wei J; Chen H; Qiu X; Hu H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):695-701. PubMed ID: 27353107
[TBL] [Abstract][Full Text] [Related]
43. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
44. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals.
Randeva HS; Lewandowski KC; Komorowski J; Murray RD; O'Callaghan CJ; Hillhouse EW; Stepien H; Shalet SM
Circulation; 2004 May; 109(20):2405-10. PubMed ID: 15123527
[TBL] [Abstract][Full Text] [Related]
45. [Effect of Dahuang Zhechong Pills combined with TACE on VEGF, MMP-2, TGF-β1 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type)].
Dai CM; Jin S; Zhang JZ
Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(3):722-729. PubMed ID: 33645040
[TBL] [Abstract][Full Text] [Related]
46. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
Paisley AN; O'Callaghan CJ; Lewandowski KC; Parkinson C; Roberts ME; Drake WM; Monson JP; Trainer PJ; Randeva HS
J Clin Endocrinol Metab; 2006 Nov; 91(11):4635-40. PubMed ID: 16926249
[TBL] [Abstract][Full Text] [Related]
47. [Clinical significance of matrix metalloproteinase-9/tissue inhibitors of matrix metalloproteinase -1 imbalance in maternal serum, amniotic fluid, umbilical cord serum in patients with premature rupture of the membranes].
Lu D; Wang ZX; Wang XL; Gu XW; Wang YX; Fu D
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):20-4. PubMed ID: 16635322
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.
Duan J; Yang Z; Liu D; Shi Y
J BUON; 2018; 23(5):1402-1406. PubMed ID: 30570865
[TBL] [Abstract][Full Text] [Related]
49. [Clinical significance of detecting VEGF, CD44v6, MMP-2, and MMP-9 in malignant ascites].
Sun XM; Dong WG; Yu BP; Luo HS; Yu JP
Ai Zheng; 2004 Jan; 23(1):85-9. PubMed ID: 14720382
[TBL] [Abstract][Full Text] [Related]
50. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
51. Expression of VEGF and HIF-1α in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis.
Zhu P; Ou Y; Dong Y; Xu P; Yuan L
Onco Targets Ther; 2016; 9():3031-7. PubMed ID: 27284254
[TBL] [Abstract][Full Text] [Related]
52. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma.
Zarbá JJ; Jaremtchuk AV; Gonzalez Jazey P; Keropian M; Castagnino R; Mina C; Arroyo G;
Ann Oncol; 2003 Aug; 14(8):1285-90. PubMed ID: 12881394
[TBL] [Abstract][Full Text] [Related]
53. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
54. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas.
Ueda M; Terai Y; Yamashita Y; Kumagai K; Ueki K; Yamaguchi H; Akise D; Hung YC; Ueki M
Int J Cancer; 2002 Mar; 98(3):335-43. PubMed ID: 11920583
[TBL] [Abstract][Full Text] [Related]
55. Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer.
Sawada M; Oishi T; Komatsu H; Sato S; Chikumi J; Nonaka M; Kudoh A; Osaku D; Harada T
Int J Clin Oncol; 2019 Dec; 24(12):1612-1619. PubMed ID: 31236742
[TBL] [Abstract][Full Text] [Related]
56. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Mitsuhashi A; Suzuka K; Yamazawa K; Matsui H; Seki K; Sekiya S
Cancer; 2005 Feb; 103(4):724-30. PubMed ID: 15637689
[TBL] [Abstract][Full Text] [Related]
57. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma.
Mell LK; Xu R; Yashar CM; McHale MT; Einck JP; Mayadev J; Lee E; Binder P; Rash D; Eskander R; Heide ES; Plaxe SC; Mundt AJ; Saenz CC
Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):964-973. PubMed ID: 32334034
[TBL] [Abstract][Full Text] [Related]
58. Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial.
Umanzor J; Aguiluz M; Pineda C; Andrade S; Erazo M; Flores C; Santillana S
Gynecol Oncol; 2006 Jan; 100(1):70-5. PubMed ID: 16288803
[TBL] [Abstract][Full Text] [Related]
59. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer.
Nagakawa Y; Aoki T; Kasuya K; Tsuchida A; Koyanagi Y
Pancreas; 2002 Mar; 24(2):169-78. PubMed ID: 11854622
[TBL] [Abstract][Full Text] [Related]
60. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
